Prospective study evaluates Helicobacter pylori's role in metabolic dysfunction-associated steatotic liver disease risk, suggesting implications for prevention strategies.
Key Points
The study aims to explore the association between H. pylori infection and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD).
Analyzed UK Biobank participants aged 40-69 years with H. pylori serostatus data (N=4,246).
Used Cox models to estimate hazard ratios, adjusting for demographic and lifestyle factors.
Conducted a meta-analysis of seven additional prospective cohorts with 36,145 participants and 6,979 MASLD cases.
Approximately 35.1% of UK Biobank participants were seropositive for H. pylori.
H. pylori seropositivity showed a marginal association with MASLD risk (HR, 1.88; 95% CI, 0.92-3.82).
CagA seropositivity was significantly associated with increased MASLD risk (HR, 2.40; 95% CI, 1.17-4.92).